UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis.

Publisher: Clinical And Experimental Rheumatology S.A.S Country of Publication: Italy NLM ID: 8308521 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0392-856X (Print) Linking ISSN: 0392856X NLM ISO Abbreviation: Clin Exp Rheumatol Subsets: MEDLINE

Publication: Pisa : Clinical And Experimental Rheumatology S.A.S
Original Publication: Pisa, Italy : Pacini editore, [1983-

Acute Kidney Injury/*diagnosis ; Acute Kidney Injury/*therapy ; Hypertension/*diagnosis ; Hypertension/*therapy ; Nephrology/*standards ; Renal Replacement Therapy/*standards ; Rheumatology/*standards ; Scleroderma, Systemic/*complications; Acute Kidney Injury/etiology ; Acute Kidney Injury/mortality ; Angiotensin-Converting Enzyme Inhibitors/administration & dosage ; Anti-Arrhythmia Agents/administration & dosage ; Anticonvulsants/administration & dosage ; Antihypertensive Agents/administration & dosage ; Consensus ; Critical Pathways/standards ; Drug Administration Schedule ; Evidence-Based Medicine/standards ; Humans ; Hypertension/etiology ; Hypertension/mortality ; Predictive Value of Tests ; Risk Factors ; Scleroderma, Systemic/diagnosis ; Scleroderma, Systemic/mortality ; Scleroderma, Systemic/therapy ; Treatment Outcome ; United Kingdom

The UK Scleroderma Study Group developed guidelines on the diagnosis and management of scleroderma renal crisis (SRC) based on best available evidence and clinical experience. SRC is characterised by the acute onset of severe hypertension and acute kidney injury. Current strategies to reduce the associated morbidity and mortality include identifying at risk patients to aid early diagnosis. ACE inhibitor therapy should be lifelong in all patients, regardless of whether they require renal replacement therapy. Patients with SRC may recover renal function up to 3 years after the crisis, most often within 12 to 18 months.

MR/K015230/1 United Kingdom MRC_ Medical Research Council

0 (Angiotensin-Converting Enzyme Inhibitors)
0 (Anti-Arrhythmia Agents)
0 (Anticonvulsants)
0 (Antihypertensive Agents)

Date Created: 20161018 Date Completed: 20170117 Latest Revision: 20220129

20240628

27749244